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Serum albumin‐coated bone allografts (BoneAlbumin) have successfully supported bone
regeneration in various experimental models by activating endogenous progenitors.
However, the effect of tissue aging, linked to declining stem cell function, has yet to
be explicitly examined within the context of BoneAlbumin's regenerative capacity. Stem
cell function was tested with an in vitro attachment assay, which showed that albumin
coating increases stem cell attachment on demineralized bone surfaces in an aging cell
population. Bone regeneration was investigated in vivo by creating critical size bone
defects on the parietal bones of aging female rats. Demineralized bone matrices with
and without serum albumin coating were used to fill the defects. Bone regeneration
was determined by measuring the density and the size of the remaining bone defect
with computed tomography (CT). Microcomputed tomography (MicroCT) and mechan-
ical testing were performed on the parietal bone explants. In vivo CT and ex vivo
microCT measurements showed better regeneration with albumin‐coated grafts. Addi-
tionally, the albumin‐coated group showed a twofold increase in peak fracture force
compared with uncoated allografts. In the present study, serum albumin‐coated
demineralized bone matrices successfully supported faster and functionally superior
bone regeneration in aging rats. Because stem cell function, a key contributor of bone
remodelling, decreases with age and serum albumin is an effective activator of endog-
enous progenitor cells, this method could be an effective and safe adjuvant in bone
regeneration of aging adult and osteo‐compromised populations.
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Endogenous stem cell function is one of the most important factors
contributing to proper tissue healing. Mesenchymal stem cells (MSCs)
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bone injury, highlighting the role of local progenitors in bone
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HORVÁTHY ET AL. 417regeneration (Colnot, 2009). However, aging tissue, linked to dimin-
ished stem cell function, can result in inferior and slower tissue remod-
elling, including compromised bone healing (Liu, Xia, & Li, 2015).
Osteoporosis, a diseased bone state that generally develops with
increasing age, also affects the regenerative potential of bone tissue
and increases the likelihood of traumatic fracture injuries. The medical
cost of osteoporosis and fractures in older adults was estimated at $22
billion in the United States alone in 2008 (Blume & Curtis, 2011). Con-
sequently, aging adults are susceptible to prolonged hospitalization and
dramatically affected functional status as a result of compromised bone
quality and regenerative capacity (Office of the Surgeon General [US],
2004). Additionally, about 15% of all fractures in the United States
require bone grafting to support proper tissue healing (Khanzada, Holy,
Jerry Volenec, & Bruder, 2008). For these reasons, adequate bone sub-
stitution and subsequent treatment modalities remain a dire challenge
in aging adult and osteo‐compromised populations.
Serum albumin‐coated bone allograft (BoneAlbumin) has been inten-
sively investigated lately, with outcomes data demonstrating an ability of
BoneAlbumin to facilitate new bone formation in non‐union and critical
size defect models in rats (Horvathy, Vacz, et al., 2016; Skaliczki et al.,
2013; Weszl et al., 2012). BoneAlbumin was also shown to decrease
donor site morbidity and enhance bone formation after anterior cruciate
ligament reconstruction with bone‐patellar tendon‐bone autografts
(Schandl et al., 2016). Moreover, in a thorough review article, the albumin
molecule was shown to have an important and potentially active but not
yet completely understood role in bone regeneration (Horvathy, Simon,
et al., 2016). Additionally, stem cell function was tested on various serum
albumin‐coated surfaces. It was shown that the serum albumin coating
supports stem cell attachment and proliferation, suggesting that serum
albumin‐coated biomaterials can be used as vehicles for cell transplanta-
tion (Bernards, Qin, & Jiang, 2008; Horvathy et al., 2013; Liu et al.,
2014; Weszl et al., 2012). From these studies, the authors concluded that
the BoneAlbumin technique increases local albumin concentration, lead-
ing to endogenous stem cell activation. As a result, a higher number of
progenitors are present at the injury site, permitting almost complete
bone healing even in critical size defects.
Accordingly, given BoneAlbumin's robust facilitation of bone for-
mation and stem cell function, the aim of the present study was to
investigate whether such a regenerative modality could yield faster
and mechanically superior ossification in an aging rat model. If such
findings are substantiated here within, the implications for treatment
in the aforementioned aging adult and osteo‐compromised demo-
graphics would be clinically advantageous.2 | MATERIALS AND METHODS
2.1 | Animals
Because female rats enter menopause between the ages of 15 and
20 months, female Wistar rats (animal) older than 20 months (and
younger than 24 months) were used for all experiments (Sengupta,
2013). The animals were maintained on lab chow and tap water ad
libitum with 12‐hr day/night cycle in the animal facility of the Institute
of Clinical Experimental Research in Budapest. The investigation wasapproved by the local animal research committee according to the
guidelines for animal experimentation (date of issue: 2009.10.07; reg-
istration number: 22.1/2960/003/2009)2.2 | Stem cell harvest and culture
Animals were euthanized with urethane (5 mg/ml). Both tibiae and
femora were cleaned of soft tissue and placed in 70% ethanol. Under
a sterile hood, both ends of the bones were cut, and the medulla was
flushed out slowly with 10‐ml culture medium (Dulbecco's Modified
Eagle's medium supplemented with 1‐g/L glutamine, 1‐g/L glucose,
10% fetal bovine serum, 100‐U/ml penicillin, and 100‐μg/ml strepto-
mycin) into 15‐ml tubes. Bone marrow was centrifuged at 274 g for
8 min at room temperature and was placed in 100‐mm Petri dishes.
After harvesting, Bone marrow‐derived mesenchymal stromal cells
(BMSCs) were maintained at 5% CO2 level at 37°C. Two days later,
the culture was washed in Dulbecco's phosphate‐buffered saline,
and fresh culture medium was given every 48 hr. Cell cultures were
used when they reached 80% of confluency, before reaching the
fourth passage.2.3 | Technology background: BoneAlbumin
preparation
Animals were euthanized with urethane (5 mg/ml). Parietal bone was
identified, and cortical bone pieces were harvested with a 4‐mm inter-
nal diameter trephine bur. The demineralized bone matrix (DBM;
Graft) was prepared by following the classical method originally
described by Urist, Mikulski, and Boyd (1975). In the case of
albumin‐treated grafts (Graft + Albumin; BoneAlbumin), protocol was
followed by the guidelines of OrthoSera GmbH: graft soaking in 20%
human albumin solution (Biotest, Hungary) was performed prior to
standard freeze drying (frozen at −80°C and freeze dried at −50°C
overnight). The albumin content in the BoneAlbumin group was deter-
mined previously (Horvathy, Vacz, et al., 2016). All chemicals were
purchased from Sigma‐Aldrich Co., Budapest, Hungary.2.4 | In vitro attachment
Prepared DBM grafts with and without albumin were put into 96 well
ultra‐low attachment wells (Costar, Corning Inc.). A 200‐μl cell suspen-
sion containing 50,000 rat BMSCs and stem cell media were co‐
cultured with the grafts for 6 and 12 hr. Cellular attachment was mea-
sured with methylthiazole tetrazolium assay (MTT, Sigma‐Aldrich Co.;
Holst Hansen, 1998). Briefly, after 6 and 12 hr of co‐culture, grafts
were allocated in a new 96‐well plate, and fresh media (200 μl) con-
taining 5‐mg/ml MTT (1:9) were added (37°C, 1 hr). After 1 hr of incu-
bation, MTT‐containing media were removed, and 200‐μl propanol
was added for 1 hr under gentle shaking. The absorbance of MTT
was measured using a spectrophotometer at the characteristic wave-
length of 570 nm. The background was measured at 690 nm. Because
absorbance values reflect on metabolic activity, increased optical den-
sity suggests better cell attachment.
418 HORVÁTHY ET AL.2.5 | Experimental protocol in vivo
In the in vivo experiment, critical size bone defects were created on
the parietal bones of the aging animals. Bone formation was moni-
tored with computed tomography (CT) on the 5th and 11th post‐
operative week. On the 11th week, parietal bones were harvested
for microcomputed tomography (microCT) scans and mechanical test-
ing. Three experimental groups were established: albumin‐coated
DBMs (Graft + Albumin; BoneAlbumin), uncoated DBMs (Graft), and
unfilled control (sham). Thirteen aging animals were involved in the
present experiment, each with two randomly filled bone defects. Nine
rats with 18 bone defects were examined with CT, microCT, and
mechanical testing; accordingly, each experimental group occupied a
total of six defects. Four animals with randomly filled defects were
used for histologic purpose only.2.6 | Surgical procedure
The surgical procedure was performed as described by Spicer et al.
(2012) in Nature Protocols. Under ketamine–xylazine (100–10 mg/kg,
Richter Gedeon Plc., Budapest, Hungary – Sigma‐Aldrich Co.) anaes-
thesia, and after proper disinfection, the skin was incised over the
parietal bone of each animal. Periosteum was carefully elevated from
the bone. Bone defects were created using a 4‐mm trephine bur
(external diameter) on both parietal bones. DBMs (Graft) with and
without albumin were used to fill the defects, and the periosteum
was united in the midline with a thin absorbable suture (6–0 Vicryl,
Johnson & Johnson, Janssen‐Cilag Ltd., Hungary).2.7 | Computed tomography
Under ketamine–xylazine anaesthesia, CT was performed with a Phil-
lips Brilliance 16 Slice CT machine (Philips International B.V. Amster-
dam, The Netherlands). Axial slices were obtained with 120 kV and
300 mA (slice thickness: 0.8 mm, increment: 0.4 mm, collimation:
16 × 0.75 mm, rotation time: 0.75 s, and pitch: 0.4). Images from the
CT scan were analysed to determine bone density. Density was
reported using the Hounsfield unit (HU) scale. Circular region of inter-
est (ROI) was set on the fifth post‐operative week for every defect.
Reference points were used to set the same ROI at each time point.
Area of the remaining bone defect was measured from the CT scans.
Windows were set to visualize animal bone without soft tissue back-
ground (2572/1595 Window/Center). The remaining bone defect
was calculated on an enlarged reconstructed image, with freehand
technique. The area of the bone defect (mm2) was compared between
the albumin‐coated, uncoated allografts, and empty defects.2.8 | Ex vivo microCT
The harvested parietal bones were scanned using a microCT scanner
(Skyscan 1172 X‐ray microtomograph, Kontich, Belgium) at 59 kV,
167 μA with a 23 μm3 isovolumetric pixel size. The centre of the bone
defect was determined via horizontal and coronal images utilizing
CTAn analysis software. On coronal images, a circular ROI with 150pixels of radius was drawn, and 100 slices were selected cranial
and caudal from the centre. As described previously, bone volume
per tissue volume (BV/TV) was calculated to determine the
relative bone content (%) in the defect area and in uninjured parts
(Kallai et al., 2011).2.9 | Histology
Four animals with randomly filled defects were sacrificed after the
11th post‐operative week. Paraffin sections from the formalin‐fixed
parietal bones were stained with haematoxylin and eosin.2.10 | Mechanical push‐out testing
Mechanical push‐out testing was performed with an Instron 5566
device (Instron, Norwood, MA, USA) according to Kretlow's method
(Kretlow et al., 2010). A custom‐made holder was created to hold
the parietal bone. The tissue samples were gently fixed between two
flat surfaces with a 5‐mm hole in the middle. The graft was guided
to the centre of the holder. To determine the breaking force, the bone
tissue was loaded with a 2.5‐mm diameter rod with a flat bottom and
rounded edges at 10 mm/min cross‐head speed, whereas load–
displacement data was registered every 100 ms. The force was regis-
tered as the rod was pressed through the bone. Peak breaking force
(N) of the samples was identified by the highest force measured. The
slope of the triangular shaped load–displacement curves represented
material stiffness (N/mm2).2.11 | Statistical analysis
All of the values are reported as the means ± standard error of the
mean. The statistical analysis was performed with t test and one‐
way analysis of variance with Bonferroni multiple comparison tests
using the GraphPad Prism statistical software. Probability values of
p < 0.05 were considered significant.3 | RESULTS
3.1 | In vitro attachment
Decreased cell function was apparent in the aging tissue population,
with attached cell number post‐harvest definitively lower than with
cells originating from young animals. Furthermore, it took approxi-
mately 3 weeks to reach the desired cell number (~800,000 cells/Petri
dish). Once this was reached, the attachment assay was started. After
6 hr of incubation, the albumin‐coated grafts attached more than
twice as many cells as the uncoated grafts (Graft + Albumin:
0.12 ± 0.02 AU; Graft: 0.06 ± 0.01 AU; p < 0.01). After 12 hr of incu-
bation, cell number did not change on the albumin‐coated surface.
There was a slight increase in cell number on the surface of uncoated
grafts after 12 hr, but it was still significantly lower compared with the
albumin‐coated grafts (Graft + Albumin: 0.11 ± 0.01 AU; Graft:
0.07 ± 0.01 AU; p < 0.5; Figure 1).
FIGURE 1 Cell attachment on the allograft surface in vitro. The
panel shows absorbance values (arbitrary unit) after 6 and 12 hr
after cell seeding. Albumin‐coated group presented significantly better
cell adherence after each time point (n = 6, error bars:
mean ± standard error of the mean, one‐way analysis of variance,
**p < 0.01, *p < 0.05)
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Bone formation was investigated with CT on the 5th and 11th post‐
operative week by calculating the remaining bone defect and measur-
ing the density (Figure 2). After 5 weeks, no statistically significant dif-
ferences in bone defect density were found between the experimental
groups; however, the albumin‐coated group did show the smallest
remaining bone defect (Graft + Albumin: 5.47 ± 1 mm2; Graft:
7.07 ± 1.6 mm2; sham: 8.27 ± 0.95 mm2). After 11 weeks, the differ-
ences between the study groups became more evident. At this time
point, the albumin‐coated group showed significantly lower remaining
bone defect compared with the empty defects, although the bone gap
was not completely closed. By contrast, the defects left empty showed
very low healing with a relatively large remaining bone defect on the
11th week (Graft + Albumin: 2.2 ± 1.08 mm2; Graft:
4.85 ± 1.83 mm2; sham: 7.6 ± 0.93 mm2; p < 0.05).
The same findings were found in the density measurements. After
5 weeks, no significant differences were found, but the albumin‐
coated group showed the highest value (Graft + Albumin:
588 ± 38 HU; Graft: 492 ± 54 HU; sham: 458 ± 47 HU). By 11 weeks,
the albumin treated group showed significantly higher density values
compared with the unfilled controls (Graft + Albumin: 802 ± 60 HU;
Graft: 646 ± 91 HU; sham: 529 ± 58 HU; p < 0.05; Figure 2).FIGURE 2 Computed tomography measurements of new bone formation
unit [HU]). Albumin‐coated allograft showed significantly higher density va
(mm2). Albumin‐coated allograft group shows significantly lower remaining
error of the mean, one‐way analysis of variance,*p < 0.05)3.3 | Ex vivo microCT and histology
The BV/TV values of uninjured parietal bones were 20 ± 0.2%, which
represents 100% (normalized) on Figure 3. MicroCT scans of injured
parietal bones were compared with the uninjured bone. As expected,
the measurements showed open bone defects and low BV/TV values
in the unfilled (sham) group. Increased, but not significant, bone
healing was seen with uncoated allografts. However, in the albumin
enhanced group, significantly higher BV/TV values were observed
compared with empty control group (Graft + Albumin: 11 ± 2.6%;
Graft: 9 ± 2.5%; sham: 1 ± 0.4% HU; p < 0.05; Figure 3). Microscopic
analysis also showed better bone regeneration in the albumin‐coated
group. In the sham operated defects, only connective tissue was
observed. Bone edges were round shaped, indicating the termination
of the regenerative process. Uncoated allografts, on the other hand,
resulted in more intense bone formation, whereas albumin‐coated
allografts showed even better osteogenesis and tissue remodelling
after the 11th post‐operative week (Figure 3).3.4 | Mechanical push‐out testing
Peak breaking force and material stiffness were measured on samples
from the uncoated and albumin‐coated groups (Figure 3). Failure of
the bone tissue occurred at the graft/host interface in all cases. Frac-
ture force of the albumin‐coated group was two times higher com-
pared with the uncoated bone grafts. (Graft + Albumin: 26.8 ± 4.5;
Graft: 14.3 ± 1.8 N; p < 0.05). The albumin‐coated grafts also showed
higher but not significant stiffness values (Graft + Albumin:
34 ± 3.5 N/mm2; Graft: 25.8 ± 4.9 N/mm2; p = 0.2; Figure 4).4 | DISCUSSION
In the present study, the authors showed that stem cells originating
from aging rats do not readily attach to DBM surfaces, but with the
use of albumin coating stem cell, adherence increases significantly.
Additionally, albumin‐coated DBM produced significantly faster bone
formation and stronger new bone in critical size calvaria defects of
the aging rats.in vivo. Panel (a) shows density values of the defect area (Hounsfield
lues after the 11th week. Panel (b) shows the remaining bone defect
bone defect after the 11th week (n = 6, error bars: mean ± standard
FIGURE 3 Ex vivo microcomputed tomography analysis and histology of calvaria defects at the 11th post‐operative week. Panel (a) shows
qualitative analysis of regenerated bone in the defect site, showing significant difference between the albumin‐coated allograft and unfilled
control group (n = 6, error bars: mean ± standard error of the mean, one‐way analysis of variance, *p < 0.05). Panels (b, c, and d) show
representative histologic images of empty, uncoated, and albumin‐coated filling, respectively. Panels (e, f, and g) shows representative
microcomputed tomography images of empty, uncoated, and albumin‐coated filling, respectively
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FIGURE 4 Mechanical testing. Panel (a)
shows peak breaking force (N) of the
implanted material after 11 weeks. Panel (b)
shows the stiffness (N/mm2) of the implanted
material after 11 weeks. Significantly higher
breaking force can be seen in the albumin‐
coated group (n = 6, error bars:
mean ± standard error of the mean, t test,
*p < 0.05)
HORVÁTHY ET AL. 421As mentioned previously, stem cell function plays an essential role
in bone regeneration. In order to increase the number of stem cells at
the injury site, Hernigou, Poignard, Zilber, and Rouard (2009)
transplanted autologous bone marrow into necrotic femoral heads
and found better outcomes in patients receiving higher number of
progenitors. Goodman and Hwang (2015) found similar results with
the same technique treating young individuals with secondary
osteonecrosis of the knee. However, stem cell functionality decreases
with age, thereby increasing the need for high multipotent cell number
at the injury site (Quarto, Thomas, & Liang, 1995; Shigeno & Ashton,
1995). According to these results, stem cell therapy could be a useful
tool for clinicians, but a population of young donor cells is necessary
to reach optimal regeneration in the elderly. Allogenic cell delivery,
on the other hand, raises regulatory, immunologic, and ethical ques-
tions that hinder this therapeutic option (Yim, 2005). Therefore,
targeting the endogenous stem cell population seems to be a reason-
able strategy. With this in mind, the authors showed that serum
albumin‐coated bone allograft (BoneAlbumin) successfully supports
bone regeneration in various experimental models. The idea behind
the phenomenon is that locally increased albumin concentration
induces endogenous progenitor recruitment, resulting in the presence
of a higher cell number to support the tissue remodelling phase
(Horvathy, Simon, et al., 2016). Evidence of stem cell activation was
supported by a first‐in‐human investigation, in which large albumin‐
coated structural allografts were used to support recovery after total
joint revision arthroplasty, with single photon emission computed
tomography (SPECT) analysis showing increased osteoblast activation
even 1 year after operation (Klara, Csonge, Janositz, Csernatony, &
Lacza, 2014). This also suggests that albumin could be a successful
adjuvant in the aging and/or elderly population to overcome the
diminished healing potential caused by decreasing stem cell function.
The idea is strongly supported by the current experiment, where albu-
min coating was shown to attach twice as many BMSCs compared
with uncoated DBMs. This ratio was nearly the same in previous work,
in which stem cells originating from young donors were used
(Horvathy, Vacz, et al., 2016). Those results showed the same attach-
ment pattern, but the cell number was twofold higher at every time
point, indicating the decreased functionality of aging multipotent cells.
Additionally, albumin‐coated DBM was a successful bone substitute in
young specimens, resulting in nearly complete regeneration on the
seventh post‐operative week (Horvathy, Vacz, et al., 2016). In the
present study, the albumin‐coated DBMs also resulted in significantly
better bone healing compared with the uncoated material in remainingbone defect, density, BV/TV, and peak fracture force, even though the
values showed less intensive bone regeneration, because this popula-
tion did not reach full consolidation even after the 11th post‐operative
week. One limitation of the present work is the size of the study
groups, but even with this element number, we observed both the
reduced healing potential and the beneficial effects of albumin, sug-
gesting that the population was adequately chosen for the
experiment.5 | CONCLUSION
Serum albumin‐coated bone allograft (BoneAlbumin) showed effec-
tiveness in bone substitution in several ways by activating the endog-
enous stem cell population. Because stem cell function generally
declines with age, aging and osteo‐compromised patients may benefit
from this technique. This method achieves a faster and more complete
regeneration, facilitating recovery and potentially decreasing the risk
of refracture. The authors emphasize that implication for clinical prac-
tice remains that of extrapolation; however, the scalability of such a
technology presents as a high potential downstream orthopaedic
modality.
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